Effect of calcium and vitamin D supplements as an adjuvant therapy to metformin on lipid profile in vitamin D deficient/insufficient polycystic ovary syndrome patients: A Randomized, Placebo-Controlled Clinical Trial
*Corresponding Author E-mail: firstname.lastname@example.org
This study aims to investigate the impact of combining calcium and vitamin D supplements with metformin on lipid profile in vitamin D deficient/insufficient polycystic ovary syndrome (PCOS) women.
A randomized, placebo-controlled clinical trial.
Damascus University of Obstetrics and Gynecology Hospital and Orient Hospital, in Damascus, Syria.
Materials and methods
Forty PCOS women with 25-hydroxyvitamin D < 30 ng/mL were randomly assigned to take either metformin (1500 mg/daily) plus placebo or metformin (1500 mg/daily) plus calcium (1000 mg/daily) and vitamin D3 (6000 IU/daily) orally for 8 weeks. Fasting serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), triglyceride (TG) and non-HDL cholesterol (non-HDL) were detected at the baseline and after 8 weeks of intervention.
Of all participants, thirty-four completed the study. After 8 weeks of intervention, calcium and vitamin D levels increased significantly in the supplementation group, but no significant changes in the lipid profile were noticed in both groups.
Adding calcium and vitamin D to metformin therapy had no superior effect on improving lipid profile in vitamin D deficient/insufficient subjects with PCOS. The Clinical Trial Registration Number is NCT03792984.
Polycystic Ovary Syndrome, Lipid Profile, Calcium, Vitamin D, Metformin.